ClinicalTrials.gg
RecruitingNCT05868408Updated Jul 15, 2026

Effect of Partially Hydrolyzed, Whey-based Infant Formulas on Growth and Tolerability in Healthy Term Infants

An interventional study of Control Formula and Experimental Formula 1 in Infant Nutritional Physiological Phenomena, Infant Formula and Infant Health, sponsored by Société des Produits Nestlé (SPN). Recruiting at 5 sites in 2 countries. Open to participants aged 0 Days to 28 Days, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-15.

Sponsored by Société des Produits Nestlé (SPN) (part of Nestlé S.A.) · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Aug 2023; still recruiting 3 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
234
Allocation
Randomized
Ages
0 Days to 28 Days
Sex
All
01

Study summary

This study will assess the effect of partially hydrolyzed, whey-based infant formulas on growth and gastrointestinal tolerance in healthy term infants.

02

Conditions studied

  • Infant Nutritional Physiological Phenomena
  • Infant Formula
  • Infant Health
  • Infant Development
  • Growth and Development
03

In context

Lead sponsor

Société des Produits Nestlé (SPN) is the lead sponsor of 324 studies on the registry; 16 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
0 Days to 28 Days
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Written has been obtained from at least one parent (or other legally acceptable representative [LAR]), if applicable)
  2. Infant gestational age ≥37 completed weeks
  3. Infant birth weight of ≥2.5 kg and ≤4.5 kg
  4. Singleton birth
  5. For Saudi: Infant postnatal age ≤28 days (date of birth = day 0); For Philippines: Infant postnatal age ≥ 14 days and ≤ 28 days (date of birth = day 0).
  6. Mother has previously decided to fully formula-feed, and infant is no longer breastfeeding or receiving breast milk
  7. Infant's parent(s)/LAR is of legal age of majority, must understand the informed consent form and other relevant study documents, and is willing and able to fulfill the requirements of the study protocol

Exclusion criteria

Exclusion Criteria:

  1. Chronic infectious, metabolic, genetic illness or other disease, including any condition that impacts feeding or growth
  2. Major congenital or chromosomal abnormality known to affect growth (e.g., congenital heart disease, cystic fibrosis)
  3. Maternal medical conditions known to affect infant growth (e.g., untreated preeclampsia or gestational diabetes)
  4. Infants with special dietary needs other than standard infant formula
  5. Infants with known (or symptoms suggestive of) cow's milk protein intolerance/allergy, or lactose intolerance or severe food allergies that impact diet
  6. Child has other medical or psychiatric condition that, in the judgement of the investigator, would make the child inappropriate for entry into the study
  7. Currently participating or having participated in another interventional clinical trial prior to enrollment
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
234 participants (estimated)

Study arms

  • Active comparator
    Control formula

    CTRL, an infant formula with minimum protein content of 1.8g intact protein/100kcal

    Other: Control Formula

  • Experimental
    Experimental formula 1

    EXPL1, an infant formula with minimum protein content of 1.9g hydrolyzed protein/100kcal

    Other: Experimental Formula 1

  • Experimental
    Experimental formula 2

    EXPL2, an infant formula identical to EXPL1 but manufactured using a different partially hydrolyzed milk protein base

    Other: Experimental Formula 2

Interventions

  • OtherControl Formula

    Infant formula made with intact protein - minimum 1.8g protein/100kcal

  • OtherExperimental Formula 1

    Infant formula made with hydrolyzed protein - minimum 1.9g protein/100kcal

  • OtherExperimental Formula 2

    Infant formula made with hydrolyzed protein - minimum 1.9g protein/100kcal

06

What researchers measure

Primary outcomes

  1. Difference in growth in first 4 months of life between control and experimental groups

    To demonstrate that growth from enrollment to age 4 months of infants fed experimental formula 1 (EXPL1) or experimental formula 2 (EXPL2) is non-inferior to that of infants fed control formula (CTRL). This is measured by weight gain velocity (g/day).

    Time frame: From enrollment to age 4 months

  2. Equivalence in growth in first 4 months of life in experimental groups

    To demonstrate that growth from enrollment to age 4 months is equivalent between infants fed EXPL1 or EXPL2. This is measured by weight gain velocity (g/day).

    Time frame: From enrollment to age 4 months

Secondary outcomes

  1. Gastrointestinal (GI) tolerance

    GI tolerance assessed using the Infant Gastrointestinal Symptom Questionnaire (IGSQ). IGSQ scores range from 13 to 65, with lower scores indicating lower GI symptom burden.

    Time frame: Enrollment and age 4, 6, and 12 months

  2. Stooling pattern

    Stool frequency and consistency assessed using a 3-day infant stool diary.

    Time frame: Age 2 and 4 months

  3. Atopic dermatitis severity

    Atopic dermatitis severity assessed using the Patient Oriented Eczema Measure (POEM). POEM scores range from 0 to 28, with lower scores indicating lower atopic dermatitis severity.

    Time frame: Enrollment and age 4, 6, and 12 months

  4. Allergy-related symptoms

    Allergy-related symptoms assessed using the Multi-Organ System Questionnaire for Infants (MOSQ-I). MOSQ-I scores range from 0 to 105, with lower scores indicating lower allergy-related symptom burden.

    Time frame: Enrollment and age 4, 6, and 12 months

  5. Dietary intake

    Total energy and macronutrient intake calculated from food recalls / diaries

    Time frame: Age 6 months

  6. Weight

    Weight (g)

    Time frame: Enrollment and age 1, 2, 3, 4, and 6 months

  7. Length

    Length (cm)

    Time frame: Enrollment and age 1, 2, 3, 4, and 6 months

  8. Head circumference

    Head circumference (cm)

    Time frame: Enrollment and age 1, 2, 3, 4, and 6 months

  9. Weight-for-age z-score

    Weight-for-age z-score based on World Health Organization (WHO) and Saudi Arabian growth charts.

    Time frame: Enrollment and age 1, 2, 3, 4, and 6 months

  10. Weight-for-length z-score

    Weight-for-length z-score based on World Health Organization (WHO) and Saudi Arabian growth charts.

    Time frame: Enrollment and age 1, 2, 3, 4, and 6 months

  11. Length-for-age z-score

    Length-for-age z-score based on World Health Organization (WHO) and Saudi Arabian growth charts.

    Time frame: Enrollment and age 1, 2, 3, 4, and 6 months

  12. Head circumference-for-age z-score

    Head circumference-for-age z-score based on World Health Organization (WHO) and Saudi Arabian growth charts.

    Time frame: Enrollment and age 1, 2, 3, 4, and 6 months

Other outcomes

  1. Stool microbiota composition

    Stool microbiota composition assessed using shotgun metagenomic analysis

    Time frame: Age 4 months

  2. Stool microbiota metabolism

    Stool organic acids and other metabolites

    Time frame: Age 4 months

  3. Fecal peptides

    Fecal milk-derived peptides

    Time frame: Age 4 months

  4. Urinary metabolomic profile

    Untargeted analysis of urine metabolites by H1-nuclear magnetic resonance (NMR) spectroscopy

    Time frame: Age 4 months

07

Study locations

2 of 5 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2023 (actual). Primary completion is estimated for Dec 2027, 52 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 16, 2023
First posted
May 22, 2023
StartActual
Aug 17, 2023
Primary completionEst.
Dec 2027
CompletionEst.
Jun 2028
Last update
Jul 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05868408
Responsible party
Sponsor
First posted
May 22, 2023
Start date
Aug 17, 2023
Primary completion
Dec 2027 (estimated)
Completion
Jun 2028 (estimated)
Last update
Jul 15, 2026

Study contacts

Qiaoji Li
Contact
qiaoji.li@rd.nestle.com
+861087419794

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion